AR092121A1 - Formas solidas de un compuesto antiviral - Google Patents
Formas solidas de un compuesto antiviralInfo
- Publication number
- AR092121A1 AR092121A1 ARP130102877A ARP130102877A AR092121A1 AR 092121 A1 AR092121 A1 AR 092121A1 AR P130102877 A ARP130102877 A AR P130102877A AR P130102877 A ARP130102877 A AR P130102877A AR 092121 A1 AR092121 A1 AR 092121A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- solid forms
- antiviral compound
- dimethylbutin
- methylcyclohex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se prepararon formas cristalinas sólidas y la forma amorfa del compuesto anti-VHC ácido 5-(3,3-dimetilbutin-1-il)-3-[(cis-4-hidroxi-4-{[(3S)-tetrahidrofurano-3-iloxi]metil}ciclohexil){[(1R)-4-metilciclohex-3-en-1-il]carbonil}amino]tiofeno-2-carboxílico (Compuesto 1) y se caracterizaron en estado sólido. También, procesos para su fabricación y métodos para utilizar las formas cristalinas. Compuesto útil para utilizar en el tratamiento de la hepatitis C. Reivindicación 1: Un hidrato cristalino del ácido 5-(3,3-dimetilbutin-1-il)-3-[(cis-4-hidroxi-4-{[(3S)-tetrahidrofurano-3-iloxi]metil}ciclohexil){[(1R)-4-metilciclohex-3-en-1-il]carbonil}amino]tiofeno-2-carboxílico (Compuesto 1, Forma I) caracterizado porque tiene un difractograma de rayos X en polvo que comprende por lo menos tres de los siguientes picos: 4,0, 7,3, 8,1, 17,9, ó 21,8 º2q ± 0,2 º2q, determinado en un difractómetro usando radiación Cu-Ka.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684297P | 2012-08-17 | 2012-08-17 | |
US13/800,991 US8841340B2 (en) | 2012-08-17 | 2013-03-13 | Solid forms of an antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092121A1 true AR092121A1 (es) | 2015-03-25 |
Family
ID=50100473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102877A AR092121A1 (es) | 2012-08-17 | 2013-08-13 | Formas solidas de un compuesto antiviral |
Country Status (10)
Country | Link |
---|---|
US (2) | US8841340B2 (es) |
EP (1) | EP2885295A1 (es) |
JP (2) | JP2015524840A (es) |
AR (1) | AR092121A1 (es) |
AU (1) | AU2013302914C1 (es) |
CA (1) | CA2882119A1 (es) |
HK (1) | HK1211924A1 (es) |
TW (1) | TW201420586A (es) |
UY (1) | UY34976A (es) |
WO (1) | WO2014028343A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
ME02536B (me) * | 2009-05-13 | 2017-02-20 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
CN104974205A (zh) * | 2014-09-19 | 2015-10-14 | 苏州晶云药物科技有限公司 | 索非布韦的晶型a及其制备方法 |
EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
ES2938859T3 (es) * | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
CA3220903A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
US20050119332A1 (en) | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
US20020002199A1 (en) | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
US6887877B2 (en) | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
MXPA05006196A (es) | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
US20050052161A1 (en) | 2003-09-08 | 2005-03-10 | Scamard David Franklin | Instant charge battery |
DE10359791A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
TW200602337A (en) | 2004-02-25 | 2006-01-16 | Wyeth Corp | Inhibitors of protein tyrosine phosphatase 1B |
US7470701B2 (en) | 2004-03-30 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Substituted 2,5-heterocyclic derivatives |
DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
EP2546246A3 (en) | 2005-05-13 | 2013-04-24 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
KR20080096670A (ko) | 2006-02-15 | 2008-10-31 | 사노피-아벤티스 | 신규한 아미노 알콜-치환된 아릴티에노피리미디논, 이의 제조 방법 및 약제로서 이의 용도 |
EA201101492A1 (ru) | 2006-11-15 | 2012-09-28 | Вирокем Фарма Инк. | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций |
JP2010510191A (ja) | 2006-11-17 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス剤としての2−カルボキシチオフェン誘導体 |
EA201190007A1 (ru) | 2008-12-03 | 2012-06-29 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
EA020816B1 (ru) | 2009-07-21 | 2015-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
JP5774008B2 (ja) | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ, インコーポレイテッド | Flaviviridaeウイルスの阻害剤 |
WO2011068715A1 (en) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
PL2523950T3 (pl) | 2010-01-15 | 2017-09-29 | Gilead Sciences, Inc. | Inhibitory wirusów flaviviridae |
KR20120123678A (ko) | 2010-01-15 | 2012-11-09 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리다에 바이러스의 억제제 |
AU2011276526A1 (en) | 2010-06-28 | 2013-01-10 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
TW201306841A (zh) | 2010-12-20 | 2013-02-16 | Gilead Sciences Inc | 治療c型肝炎病毒(hcv)之方法 |
ES2561888T3 (es) | 2011-07-13 | 2016-03-01 | Gilead Sciences, Inc. | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae |
US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
-
2013
- 2013-03-13 US US13/800,991 patent/US8841340B2/en active Active
- 2013-08-09 JP JP2015527506A patent/JP2015524840A/ja active Pending
- 2013-08-09 EP EP13750475.9A patent/EP2885295A1/en not_active Withdrawn
- 2013-08-09 CA CA2882119A patent/CA2882119A1/en not_active Abandoned
- 2013-08-09 WO PCT/US2013/054406 patent/WO2014028343A1/en active Application Filing
- 2013-08-09 AU AU2013302914A patent/AU2013302914C1/en not_active Ceased
- 2013-08-13 AR ARP130102877A patent/AR092121A1/es unknown
- 2013-08-13 TW TW102128976A patent/TW201420586A/zh unknown
- 2013-08-13 UY UY0001034976A patent/UY34976A/es not_active Application Discontinuation
-
2014
- 2014-06-24 US US14/313,877 patent/US9409891B2/en active Active
-
2015
- 2015-12-24 HK HK15112677.8A patent/HK1211924A1/xx unknown
-
2018
- 2018-06-20 JP JP2018116866A patent/JP2018162278A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201420586A (zh) | 2014-06-01 |
AU2013302914B2 (en) | 2017-08-10 |
HK1211924A1 (en) | 2016-06-03 |
UY34976A (es) | 2014-02-28 |
JP2018162278A (ja) | 2018-10-18 |
AU2013302914C1 (en) | 2018-05-17 |
CA2882119A1 (en) | 2014-02-20 |
AU2013302914A1 (en) | 2015-02-05 |
EP2885295A1 (en) | 2015-06-24 |
WO2014028343A1 (en) | 2014-02-20 |
US8841340B2 (en) | 2014-09-23 |
US9409891B2 (en) | 2016-08-09 |
US20140051749A1 (en) | 2014-02-20 |
JP2015524840A (ja) | 2015-08-27 |
US20140309187A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092121A1 (es) | Formas solidas de un compuesto antiviral | |
ECSP17084267A (es) | Pirazolo[1,5a]pirimidinas como agentes antivirales | |
ZA201903161B (en) | Antiviral compositions for the treatment of infections linked to coronaviruses | |
ZA201603123B (en) | Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections | |
HK1218110A1 (zh) | 氨磺酰基-芳基酰胺及其作爲用於乙型肝炎治療的藥物的用途 | |
AR090151A1 (es) | Compuestos inhibidores de raf | |
PE20210153A1 (es) | Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2 | |
WO2014165128A3 (en) | Hepatitis b antiviral agents | |
PT3409667T (pt) | Compostos amida para o tratamento do vih | |
MD20150080A2 (ro) | Compoziţie combinată de doi compuşi antivirali | |
CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
UY34245A (es) | Compuestos antivirales para el tratamiento de la hepatitis c (hcv), y métodos de tratamiento. | |
WO2014197093A3 (en) | All water-based nanopatterning | |
CO6862153A2 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
SI2909205T1 (sl) | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij | |
ECSP11011101A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
EP2781504A4 (en) | CYCLIC COMPOUND AS WELL AS MANUFACTURING METHOD, RADIATION SENSITIVE COMPOSITION, AND RESIST PATTERN FORMING METHOD | |
MX342153B (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
EP3033080A4 (en) | Methods and compositions for increasing the effectiveness of antiviral agents | |
TWI563346B (en) | Substrate for euv mirror,method for producing substrate for euv mirror,use of said substrate and lithography method | |
SI2766367T1 (sl) | 4-amino-3-fenilamino-6-fenilpirazol(3,4-D)primidinski derivati za zdravljenje virusnih okužb, zlasti pikornavirusnih okužb | |
EP2781501A4 (en) | CYCLIC COMPOUND AS WELL AS MANUFACTURING METHOD, RADIATION SENSITIVE COMPOSITION, AND RESIST PATTERN FORMING METHOD | |
ITRI20120001U1 (it) | Impianto dentale al titanio con meccanismo di espansione interna e con lamine "l" per il blocco esterno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |